API's
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients
Esomeprazole Magnesium Pellets are gastro-resistant, enteric-coated pellets of the proton pump inhibitor (PPI) Esomeprazole. They are designed to prevent degradation in acidic conditions of the stomach and ensure targeted release in the intestine, where absorption is optimized.
| Component | Function |
|---|---|
| Esomeprazole Magnesium | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Spheres | Inert core or starter pellets |
| Hydroxypropyl Methylcellulose (HPMC) | Binder / Film former during layering |
| Talc / Colloidal Silicon Dioxide | Anti-adherent / Glidant |
| Eudragit L30D-55 or HPMCP | Enteric coating polymer – Delayed release (pH > 5.5) |
| Triethyl Citrate / PEG 6000 | Plasticizer (for polymer coating) |
| Purified Water | Solvent (removed after processing) |
Outsourcing pellets through a trusted partner like Salius Pharma can be a strategic decision to save both time and resources, without compromising on quality or compliance. Instead, partnering with Salius Pharma—a leading distributor aligned with USFDA-approved and WHO-GMP-certified manufacturers in India—allows you to leverage high-quality products, seamless logistics, and professional support under one roof.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Esomeprazole Mg Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
Esomeprazole is unstable in acidic conditions; the enteric coating ensures drug release only in the intestine (pH > 5.5), maintaining its therapeutic efficacy.
They are widely used for GERD, peptic ulcers, Zollinger-Ellison syndrome, erosive esophagitis, and NSAID-induced gastric ulcers.
The pellets are enteric coated to resist gastric acid degradation and ensure targeted release in the intestine, improving drug stability and bioavailability compared to conventional tablets.
We provide COA (Certificate of Analysis), MSDS (Material Safety Data Sheet), Stability Data, and necessary regulatory support documents.